Clinical Trials Logo

Unstable Angina clinical trials

View clinical trials related to Unstable Angina.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03906812 Withdrawn - Chest Pain Clinical Trials

A Randomized Trial of Telemetry Compared With Unmonitored Floor Admissions in ED Patients With Low-Risk Chest Pain

Start date: September 2020
Phase: N/A
Study type: Interventional

This study aims to determine, relative to telemetry admission, if admission to an unmonitored floor bed saves resources without an increased rate of adverse events in emergency department (ED) patients admitted with chest pain and low-risk features.

NCT ID: NCT02893280 Withdrawn - Clinical trials for Acute Coronary Syndrome

Acute Coronary Syndrome Sri Lanka Audit Project

ACSSLAP
Start date: April 2015
Phase: N/A
Study type: Observational

ACSSLAP is the first island wide audit project in Sri Lanka on ACS.

NCT ID: NCT02723981 Withdrawn - Coronary Disease Clinical Trials

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

COSTA
Start date: April 2016
Phase: Phase 4
Study type: Interventional

Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate - the incidence of bleedings (COSTA-Bleed) and - the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal sirolimus coated bio-engineered stent (COMBO stent) in association with short-term single antiplatelet therapy as compared to a guidelines-based strategy in patients with coronary artery disease with an indication for chronic oral anticoagulant therapy.

NCT ID: NCT01245725 Withdrawn - Clinical trials for Myocardial Infarction

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

ATLAST-PCI
Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the efficacy of tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention (PCI) plus two hours after the procedure) is more effective than placebo in the setting of standard therapies (e.g. aspirin, a thienopyridine, and unfractionated heparin or bivalirudin) among patients undergoing PCI, as assessed by the incidence of adverse cardiac ischemic events defined as death, myocardial infarction (MI), and urgent target vessel revascularization (uTVR) within 48 hours following study drug initiation. A secondary objective of this study is to assess whether tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a PCI plus two hours after the procedure) is safe compared to placebo in the setting of standard therapies (e.g. aspirin, a thienopyridine, and unfractionated heparin or bivalirudin) among patients undergoing PCI, as assessed by the incidence of non-CABG-related TIMI major bleeding within 48 hours following study drug initiation. Patient enrollment is pending.

NCT ID: NCT00337116 Withdrawn - Clinical trials for Myocardial Infarction

Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This is a randomized, double blind, placebo-controlled study, clinical trail designed to evaluate the efficacy safety and superiority of intravenous boluses of isosorbide dinitrate for the relief of acute anginal pain episodes in acute coronary syndrome patients in comparison with the usual manner of S/L isosorbide dinitrate .